Known targets — ChEMBL curated mechanism
BRAFFLT1FLT3FLT4KDRKITPDGFRBRAF1RET
The experimentally established mechanism targets of Sorafenib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR known ✓ | P35968 | 6/20 | 0.87 |
| ▸ | RAF1 known ✓ | P04049 | 12/20 | 0.80 |
| ▸ | RET known ✓ | P07949 | 4/20 | 0.80 |
| ▸ | BRAF known ✓ | P15056 | 4/20 | 0.80 |
| ▸ | PDGFRB known ✓ | P09619 | 2/20 | 0.80 |
| ▸ | KIT known ✓ | P10721 | 2/20 | 0.80 |
| ▸ | FLT1 known ✓ | P17948 | 2/20 | 0.80 |
| ▸ | FLT4 known ✓ | P35916 | 2/20 | 0.80 |
| ▸ | FLT3 known ✓ | P36888 | 2/20 | 0.80 |
| ▸ | AURKB | Q96GD4 | 3/20 | 0.87 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.87 |
| ▸ | MC4R | P32245 | 1/20 | 0.87 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.87 |
| ▸ | ABL1 | P00519 | 3/20 | 0.80 |
| ▸ | EPHA2 | P29317 | 3/20 | 0.80 |
| ▸ | MAPK14 | Q16539 | 3/20 | 0.80 |
| ▸ | MAP3K20 | Q9NYL2 | 3/20 | 0.80 |
| ▸ | RIPK2 | O43353 | 2/20 | 0.80 |
| ▸ | ABCB11 | O95342 | 2/20 | 0.80 |
| ▸ | HTR1A | P08908 | 2/20 | 0.80 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Sorafenib SCHEMBL15939735 | 0.93 | KDR (1.00) | KDRAURKBNTSR1MC4RPAX8 | |
| Sorafenib SCHEMBL162935 | 0.93 | KDR (1.00) | KDRAURKBNTSR1MC4RPAX8 | |
| Sorafenib SCHEMBL18496409 | 0.93 | KDR (1.00) | KDRAURKBNTSR1MC4RPAX8 | |
| Sorafenib SCHEMBL29919725 | 0.93 | KDR (1.00) | KDRAURKBNTSR1MC4RPAX8 | |
| Sorafenib SCHEMBL28204502 | 0.92 | KDR (0.98) | KDRAURKBNTSR1MC4RPAX8 | |
| Sorafenib SCHEMBL3660939 | 0.92 | KDR (0.98) | KDRAURKBNTSR1MC4RPAX8 | |
| Sorafenib SCHEMBL3664023 | 0.90 | KDR (0.94) | KDRAURKBNTSR1MC4RPAX8 | |
| Sorafenib SCHEMBL16051185 | 0.90 | KDR (0.94) | KDRAURKBNTSR1MC4RPAX8 | |
| Sorafenib SCHEMBL1534040 | 0.89 | RAF1 (0.93) | KDRAURKBNTSR1MC4RPAX8 | |
| Sorafenib SCHEMBL1533972 | 0.89 | RAF1 (0.93) | KDRAURKBNTSR1MC4RPAX8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 25404 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3841097-B1 | 2,6-BIS(((1H-BENZO[D]IMIDAZOL-2-YL)THIO)METHYL)PYRIDINE AND N2,N6-DIBENZYLPYRIDINE-2,6-DICARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS PHOSPHOINOSITIDE 3-KINASE (PI3K) INHIBITORS FOR TREATING CANCER | BIOMEDICAL RES FOUNDATION OF THE ACADEMY OF ATHENS BRFAA (GR) | 2026-05-20 | — | — | EP | claimed |
| EP-4743086-A2 | TREATING MYELOID DISORDERS | Mayo Foundation for Medical Education and Research (US) | 2026-05-20 | — | — | EP | claimed |
| WO-2026102161-A1 | METHODS OF TREATING OVARIAN AND PANCREATIC CANCER | CONCARLO THERAPEUTICS, INC. (US) | 2026-05-15 | — | — | WO | claimed |
| US-20260132141-A1 | PROTEIN PHOSPHATASE 2A ACTIVATORS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2026-05-14 | — | — | US | claimed |
| WO-2026087695-A1 | TREATMENT FOR METABOLIC DISORDER | SAPREME TECHNOLOGIES B.V. (NL) | 2026-04-30 | — | — | WO | claimed |
| WO-2026087680-A1 | TREATMENT FOR CARDIOVASCULAR DISEASE | SAPREME TECHNOLOGIES B.V. (NL) | 2026-04-30 | — | — | WO | claimed |
| US-20260109699-A1 | AZOLE DERIVATIVES AS SHP2 INHIBITORS | IRBM S.P.A. (IT) | 2026-04-23 | — | — | US | claimed |
| EP-4712963-A2 | SMALL MOLECULE INHIBITORS OF P27 | Concarlo Therapeutics, Inc. (US) | 2026-03-25 | — | — | EP | claimed |
| EP-4709378-A1 | COMPOUNDS FOR NOS-RELATED CANCERS AND METHODS OF USE | Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. (IL) | 2026-03-18 | — | — | EP | claimed |
| US-20260069700-A1 | BRUSH PRODRUGS AND USES THEREOF | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2026-03-12 | — | — | US | claimed |
| EP-1915151-A2 | COMBINATIONS FOR THE TREATMENT OF CANCER COMPRISING ANTI-EGFR ANTIBODY AND VEGFR INHIBITORS | Amgen, Inc (US) | 2008-04-30 | — | — | EP | claimed |
| US-20080066741-A1 | METHODS AND SYSTEMS OF DELIVERING MEDICATION VIA INHALATION | HUNTER, CHARLES ERIC | 2008-03-20 | — | — | US | claimed |
| WO-2008028926-A2 | METHODS AND COMPOSITIONS FOR THE PREDICTION OF RESPONSE TO TRASTUZUMAB CONTAINING CHEMOTHERAPY REGIMEN IN MALIGNANT NEOPLASIA | SIEMENS HEALTHCARE DIAGNOSTICS GMBH (DE) | 2008-03-13 | — | — | WO | claimed |
| US-20070281934-A1 | INDOLE DERIVATIVES AS INHIBITORS OF HISTONE DEACETYLASE | PHARMACYCLICS, INC. (US) | 2007-12-06 | — | — | US | claimed |
| WO-2007109178-A2 | INDOLE DERIVATIVES AS INHIBITORS OF HISTONE DEACETYLASE | PHARMACYCLICS, INC. (US) | 2007-09-27 | — | — | WO | claimed |
| WO-2007084670-A2 | SPECIFIC THERAPY USING INTEGRIN LIGANDS FOR TREATING CANCER | MERCK PATENT GMBH (DE) | 2007-07-26 | — | — | WO | claimed |
| WO-2007070538-A2 | ANTI-MN ANTIBODIES AND METHODS OF USING SAME | BAYER HEALTHCARE LLC (US) | 2007-06-21 | — | — | WO | claimed |
| WO-2007056470-A2 | NEUROPILIN ANTAGONISTS | GENENTECH, INC. (US) | 2007-05-18 | — | — | WO | claimed |
| WO-2006102504-A2 | COMBINATIONS FOR THE TREATMENT OF CANCER COMPRISING ANTI-EGFR ANTIBODY AND VEGFR INHIBITORS | AMGEN INC (US) | 2006-09-28 | — | — | WO | claimed |
| US-20060216288-A1 | Combinations for the treatment of cancer | AMGEN INC (US) | 2006-09-28 | — | — | US | claimed |